Cancer Archives

adc therapeutics antibody drug conjugates

News and Trends 9 Jul 2019

Update: Swiss Biotech’s Series E Expanded to €271M to Commercialize Antibody-Guided Cancer Chemotherapy

Update (09/07/2019): The Switzerland-based ADC Therapeutics has completed the final closing of a €271M ($303M) Series E round to finance the development of a phase II antibody-drug conjugate treatment for blood cancer. With its big Series E complete, the company is in a good financial position to prepare for the commercialization of its lead candidate […]

July 9, 2019 - 3 minutesmins - By Jonathan Smith

biontech cancer vaccine mrna immunotherapy

News and Trends 9 Jul 2019

BioNTech Raises Whopping €290M to Fund Personalized mRNA Vaccines for Cancer

In one of the biggest ever funding rounds in European biotech, the German company BioNTech has raised a Series B of €289.5M ($325M) to develop individualized cancer vaccines. BioNTech will use the money to fuel the clinical development of the company’s lead program — an individualized mRNA-based immunotherapy for treating melanoma, which completed a phase […]

July 9, 2019 - 3 minutesmins - By Jonathan Smith

evotec dna damage repair parp inhibitor cancer

News and Trends 8 Jul 2019

Evotec Spinoff to Develop Cancer Drugs that Block DNA Repair

Breakpoint Therapeutics, a spinoff from the German biotech Evotec, has raised €30M to develop drugs that block DNA repair mechanisms in drug-resistant cancers. Breakpoint Therapeutics aims to develop first-in-class drugs that kill cancer cells by sabotaging their DNA repair machinery. Having taken on a number of Evotec’s drug development programs, Breakpoint aims to have its […]

July 8, 2019 - 2 minutesmins - By Jonathan Smith

Why Orthotopic Tumor Models Are Key to Successful Cancer Therapies

One of the greatest challenges faced by researchers in preclinical oncology studies is the translatability of animal models. Mimicking human diseases accurately to investigate the effects of novel therapeutics is a demanding task. With the development of increasingly complex immunotherapies, biotech and pharma companies are looking for more relevant and accurate preclinical models to get […]

July 8, 2019 - 7 minutesmins - By External Contributor

melanoma yukin therapeutics antibody cancer nice

Startup Scout 5 Jul 2019

This Biotech Helps the Immune System to Infiltrate and Destroy Tumors

The Nice-based biotech company Yukin Therapeutics is developing drugs that can work together with checkpoint inhibitors to help the immune system smash tumors such as melanoma. Mission: To develop a drug that can change the tumor microenvironment to allow the immune system to infiltrate and destroy the tumor more effectively. This could give a big […]

July 5, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 1 Jul 2019

Approval Status of Cancer Cell Therapy at Risk After Halting Phase III Trial

Following an unfavorable interim analysis, Milan-based MolMed has suspended a phase III trial of its cell therapy Zalmoxis that could threaten the conditional marketing authorization the treatment received in 2016. The halted clinical trial was evaluating the effects of Zalmoxis on patients with high-risk leukemia that have received a bone marrow transplant. The cell therapy […]

July 1, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Jun 2019

Scientists Grow Head and Neck Cancer Organoids to Personalize Chemotherapy

A team of Dutch researchers has developed the first 3D organoids from patients’ head and neck cancer cells that can be kept alive for a long time, giving physicians a model to test which cancer treatments are the most effective for each patient. Head and neck cancer is an aggressive disease that often requires harsh […]

June 19, 2019 - 3 minutesmins - By Jonathan Smith

ovarian cancer astrazeneca merck lynparza dna repair

News and Trends 19 Jun 2019

EU Gives Lynparza Green Light as First-Line Ovarian Cancer Treatment

The DNA damage repair drug olaparib (Lynparza), developed by AstraZeneca and Merck, has been approved by the EU as a first-line treatment preventing the return of ovarian cancer after initial chemotherapy. The drug has already been approved by the EU and the FDA as a maintenance treatment for relapsed ovarian cancer, and as a therapy […]

June 19, 2019 - 3 minutesmins - By Jonathan Smith

In Depth 17 Jun 2019

Artificial Intelligence in Oncology: Fantasy or Reality?

Artificial intelligence promises to use the power of data to solve some of the biggest problems of our time. But can it help us treat a disease as complex as cancer? Artificial intelligence and machine learning are (not that) new technologies that have been recently boosted thanks to hardware improvements. Through algorithms, they can learn, […]

June 17, 2019 - 6 minutesmins - By Timothé Cynober

genmab janssen blood cancer multiple myeloma

News and Trends 11 Jun 2019

Janssen and Genmab Team Up Again for Another Potential Cancer Blockbuster

Janssen and the Danish biotech Genmab will collaborate to develop a new antibody that could outperform their blockbuster cancer drug Darzalex in certain types of blood cancer. Genmab will develop the antibody treatment until it completes clinical proof-of-concept studies in the blood cancers multiple myeloma and diffuse large B-cell lymphoma. At that point, Janssen will […]

June 11, 2019 - 2 minutesmins - By Jonathan Smith

In Depth 11 Jun 2019

Gamma Delta T Cells: A New Hope Against Cancer

A new wave of therapies based on a unique type of immune cells, called gamma delta T cells, has the potential to treat cancer with stronger responses and fewer side effects. Immunotherapies based on T cells are becoming a huge trend in the treatment of cancer, especially CAR-T cells. These genetically-modified T cells have shown […]

June 11, 2019 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Jun 2019

Highlights from European Biotech at ASCO 2019

European biotech companies gathered in Chicago, USA, to share the latest advances in cancer research at the biggest cancer conference of the year, ASCO 2019. This year’s conference has drawn fewer big blockbuster headlines than other years, but there was plenty to see nonetheless. There were results from many different clinical trials by big pharma […]

June 5, 2019 - 5 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us